drugset / Trial / NCT04686760

Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients

NCT04686760

Completed 278 enrolled University of Lahore
RandomizedParallel-groupOpen-labelTreatment

Summary

In current analysis moderate to severely ill Covid-19 infected patients will be nebulized with nitroglycerin, and they will be compared with the standard nebulization

Timeline

Start
2020-11-15
Primary completion
2021-12-15
Completion
2022-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitroglycerin Unknown 2 mg/ml Other

Indications